Fig. 4: Intracellular flow cytometry measurements of IL-17A, IL-17F and IFNγ in CD4 and CD8 T cells treated with duvelisib.
From: Circulating Th17 T cells at treatment onset predict autoimmune toxicity of PI3Kδ inhibitors
A Absolute number of CD4 T cells positive for the indicated cytokine at Scr (screen timepoint), C1D1 (7 days on duvelisib prior to FCR) and either 2 or 6 months post FCR, comparing patients with early toxicity (Tox) to either delayed or no toxicity (No Tox). The bottom panel is the ratio of IL17F:A. B Absolute number of CD8 T cells positive for the indicated cytokine at Scr (screen timepoint), C1 (7 days on duvelisib prior to FCR) and either 2 or 6 months post FCR, comparing patients with early toxicity (Tox) to either delayed or no toxicity (No Tox). The bottom panel is the ratio of IL17F:A. *p ≤ 0.05; **p ≤ 0.01.
